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EXECUTIVE SUMMARY
Background
There have been two sets of pre-introductory clinical trials of NORPLANT® implants in Egypt. The
Rockefeller Foundation and the Population Council supported the first trial in the early 1980s and
the Egyptian Fertility Care Society (EFCS), with support from the United States Agency for
International Development (USAID) and technical assistance from Family Health International
(FHI), conducted the second
clinical trial in 1988.
Physicians from five
university hospitals in Egypt
provided NORPLANT®
implants to 1,536 women
during the period 1988-94. An
acceptability study (EFCS
1995) indicated that 93
percent of the NORPLANT®
clients surveyed were
satisfied with the method.
Based on the positive experience gained through these clinical trials, the Ministry of Health and
Population’s (MOHP) Central Administration for Family Planning decided to proceed with the
development of the NORPLANT® Introductory Program and produced a strategy and regulations
for NORPLANT® service provision.
The program began in November 1995 when NORPLANT® service provision was re-introduced in
the five university hospitals that were included in the clinical trials. NORPLANT® service was then
introduced to more university hospitals and teaching hospitals. In November 1996, it was decided to
expand NORPLANT® services. The revised plan added the use of mobile teams, consisting of one
physician and one nurse from university or teaching hospitals. These mobile teams visited MOHP
health facilities according to predetermined schedules to provide one-day NORPLANT® services.
As of April 2000, NORPLANT® services have been provided in 11 university hospitals, 8 teaching
hospitals and 93 MOHP health facilities. The mobile teams provided NORPLANT® insertions free
of charge. However, insertions done through university and teaching hospitals as well as at the
MOHP health facilities were provided for a fee (average LE 20). In mid-August 1999 the MOHP
decided to provide NORPLANT® free of charge at all MOHP health facilities. This decision has
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substantially increased demand for NORPLANT® insertions at these sites. The MOHP and
FRONTIERS began discussing the need for investigating these service delivery aspects in 1999.
From those consultations this study emerged.
Study Objectives
The study has the following short-term objectives:
1. To assess the completeness and accuracy of the NORPLANT® central level management
information system (MIS) and client record cards, specifically related to the ability of the
NORPLANT® program to ensure the timely removal of expired NORPLANT® implants.
2. To identify factors influencing provider attitudes and motivation to provide NORPLANT®
services.
3. To develop an understanding of NORPLANT® users’ perspectives of the method,
including their satisfaction with the services they have received and their knowledge about
the need for timely removal.
Study Methods
The study employed an observational cross-sectional analysis of settings where NORPLANT®
services are currently provided. It employed 4 types of data collection instruments and 2 types of
research methods. An abbreviated audit of the client record system at selected facilities and an audit
of the central level MOHP MIS of NORPLANT® users were conducted. In addition, NORPLANT®
providers and users were interviewed.
The study compared information on clients obtained from the clinics’ client records (in clinic
registries and logbooks) to the actual client records available at the MOHP MIS central level to
assess the reliability and completeness of the recording system and to check if information on the
NORPLANT® clients recorded in the health facility logbook was also included in the central level
MIS.
A Standardized questionnaire was produced for use with all consenting physicians and nurses who
provided NORPLANT® services at the study clinics, and who were available during the data
collection period.
In addition, two categories of NORPLANT® users were requested to give consent for interviews:
1. Women who came to the study sites during the data collection period to have NORPLANT®
inserted or to receive follow-up services within one month of insertion. These women were
requested to consent to exit interviews. This group of women are referred to as “new users”.
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2. Women who began NORPLANT® use between 1-4 years ago. These women were identified by
their medical records and were contacted at their homes by the health care providers to ascertain
if they would agree to an interview at the clinic or their home. This group of women are referred
to as “continuing users”.
The study was conducted in approximately one-third (36 sites in total) of the three types of health
facilities providing services: MOHP, university and teaching hospitals, that were purposively
chosen by a panel of experts.
The study instruments were pre-tested in five clinics that were not included in the study sites. Data
collectors and supervisors participated in an intensive one-week training workshop that started on
September 30, 2000. Data collection activities began in the second week of October 2000 and lasted
for five weeks.
Findings
For all study sites, the study collected data on the mean monthly NORPLANT® caseload per clinic
during the period August 1999 - September 2000 for both insertions and removals. The figures
indicate that in general, for all the period shown, the monthly mean number of NORPLANT®
insertions per clinic is 11.3 and the median is 9.5 with a range of mean insertions of 1.8 – 40.1.
Also, the monthly mean number of removals is 1.2 and the median is 0.1, with a range of removals
of 0 – 9.6.
The majority of the physicians providing NORPLANT® services are male (62 percent) and more
than one-half of them are 40 years old or more (mean age is about 41 years). More than 90 percent
of the physicians have attained post-graduate degrees. Approximately 94 percent of the physicians
who provide NORPLANT® services have attended training courses on the insertion and removal of
NORPLANT®. Overall about one-half of the physicians who provide NORPLANT® reported a felt
need for additional training in NORPLANT® removal.
About two-thirds of the nurses are less than 40 years old, with a mean age of 34 years. Overall,
nurses reported working in NORPLANT® service provision for an average of almost two and onehalf years. However university hospital nurses had more experience in NORPLANT® service
provision (mean number of years is 8.3). Almost all of the nurses have received training in family
planning and the large majority (79 percent) have received training in NORPLANT® service
provision.
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The study compared information on clients obtained from the clinics’ client records (in clinic
registries and log books) to the actual client records available at the MOHP MIS central level to
assess the reliability and completeness of the recording system. Records that existed in both clinic
registers and MIS represented about two-thirds (64%) of the cases. One-third of clients’ records
were available in clinics’ registers but not in the MIS.
A review of accuracy of the information was conducted for client records that existed in both the
clinic and the central MIS (that produced a score of 1 for perfect fit and zero for no fit). Findings
indicated that accuracy for the insertion date is high (0.95), moderate for the insertion complications
(0.67), low for removal date (0.4) and last family planning used (0.48), and very low for the
woman’s address (0.25).
With regard to accuracy of the clients’ addresses, the study indicates that only about 56 percent of
the continuing users selected at random for the home interview were actually reached using the
locator information on the client records. An additional 37 percent of NORPLANT® clients could
not be located because their addresses were incomplete. Furthermore, in the majority of clients’
records information on the relative’s address was not collected.
During the home interview, the study also assessed if each continuing user was given a follow-up
card as well as the accuracy of the information recorded in that card. Nearly half (45%) of
continuing NORPLANT® users received a card and were still keeping it. Two-fifths (40%) received
the follow-up card but it was later lost. In 15 percent of cases, women said that they did not receive
a card. Cases in which the card was available also indicated some discrepancies in accuracy of
information recorded on the card, but overall the information on the client card corresponded with
the clinic records particularly on the year of insertion.
Physicians were asked about their views about NORPLANT® advantages and disadvantages. The
advantages most frequently mentioned were that NORPLANT® is a long-acting method (reported
by 71 percent) and that it is a safe and effective method (61 percent). About one-half of physicians
mentioned that women do not need to remember doing anything to avoid pregnancy, like taking a
pill daily. The most frequently reported disadvantage of NORPLANT® is that it causes menstrual
cycle disturbance (reported by 62% of physicians). The next most frequently mentioned
disadvantage is that it sometimes causes severe bleeding (42%), followed by difficulty of removal
(36%). In general, the study findings did not suggest the presence of negative attitudes by service
providers towards NORPLANT® as a family planning method.
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The study findings indicated a lack of consensus among physicians about NORPLANT®
contraindications and suggest the need for more training of physicians on this issue. Also,
physicians faced difficulties in NORPLANT® removal. About two-fifths (43%) of physicians who
had ever removed NORPLANT® reported that the most frequent problems met were that the site of
implanted capsules was not clear (36%) and the difficulty of removing all rods in one session
(32%).
Although the majority of physicians reported that there is a system in place to follow-up clients who
fail to make follow-up visits, about four-fifths of physicians (80%) reported that there is no
mechanism in place to do home visits for those women. The implication is that women who may
forget the removal date will not be contacted by clinic staff to be advised for removal.
The study findings indicated that about 10% of the new users had not previously used another
method before NORPLANT®. The IUD and injectables were used each by about one-third of the
new NORPLANT® users and the pill was used by about one-fourth of the women before they
switched to NORPLANT®.
This study also collected information on counseling and information given to clients by service
providers before and after NORPLANT® insertion. Almost all of the women (96%) reported being
told about the use duration of NORPLANT®, (i.e., five years). About two-thirds were told about
NORPLANT® advantages and one-half were told about NORPLANT® insertion procedures.
However, counseling on potential side-effects was provided to only 39% of the women.
The majority reported being told about the need for follow-up visits (92%). However, only 85%
reported that they received a card including the schedule for follow-up visits. Only about one-fourth
of women were told about the due date for removal before they left the clinic. In addition, about
69% of women were advised what to do in case they experienced side-effects.
The study examined the satisfaction with the NORPLANT® method and related aspects of service
provision received among new users. Almost all new clients (98%) reported that the insertion
procedure went well and no problems were faced. About (74%) reported that they didn’t feel pain
or fear during the insertion procedure. Most (89%) of the new users who received a free method
reported that they would still request NORPLANT® insertion if they were asked to pay for it. About
three-fourths (76%) of the new users who paid for the method reported that the payment made was
reasonable (mean payment for the method was LE 16.9).
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The study also collected data on the experiences of continuing users (n=624) of NORPLANT® (i.e.,
women who had NORPLANT® inserted 1-4 years ago). The two most commonly cited advantages
to NORPLANT® use among this group are its long duration (36%) and fewer side effects (24%).
Some of the continuing users mentioned that they had less side-effects with NORPLANT® or sideeffects that were more tolerable compared with other family planning methods that they tried before
NORPLANT®.
With regard to the principal disadvantage, about two-fifths (42%) of the continuing users do not
perceive any disadvantage for NORPLANT®. The most frequently reported disadvantage was that
NORPLANT® causes menstrual cycle disturbance (cited by 26%). Other reported disadvantages
included headache, weight gain and pain (reported each by about 6%).
Home interviews indicated that about 17 percent of woman (n=103) had NORPLANT® removed
before 5 years of use. Experiencing bleeding was the main cause of dissatisfaction with the method
that led to early removal (reported by about one-half of women who stopped using NORPLANT®).
An additional one-fourth mentioned that they had NORPLANT® removed because of its other sideeffects. The decision to remove NORPLANT® was primarily made by the woman herself (62%),
while 29% of the women stated that the physician recommended removal.
Both NORPLANT® continuers and discontinuers were asked about the duration of NORPLANT®
use since insertion. The study findings indicated that about one-half of woman who discontinued
NORPLANT® use had the implants removed before the second year of use. Overall, the average
duration of NORPLANT® use among continuers and discontinuers was 1.8 and 1.4 years,
respectively.
Both continuing users and discontinuers were asked about side-effects experienced during
NORPLANT® use. As expected, substantially higher proportions of NORPLANT® discontinuers
reported experiencing NORPLANT® side-effects compared to the continuers group. Among the
discontinuers group the most frequently reported side-effects experienced were severe bleeding
(47%), weight changes (39%), menstrual cycle disturbance (35%) and suffering continuous
headache (28%). For the continuers group, the most frequently reported side-effects for
NORPLANT® were menstrual cycle disturbance (30%), amenorrhoea (18%) and weight changes
(17%).
Women who had NORPLANT® removed (n=103) did report some difficulties with the removal
experience. About one-half of women said that the removal procedure was difficult (e.g. felt pain,
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too long removal time). About one tenth complained that they had to make at least two visits to the
clinic to have NORPLANT® removed.
Seventy-one percent of women who had NORPLANT® removed switched to another family
planning method after removal. Among this group, about 38% switched to the IUD, about 33%
switched to the pill, and about 26% switched to injectables.
Among all of the sample women who began using NORPLANT® between 1-4 years ago, the vast
majority reported general satisfaction with the method, and the services. About 80% reported
having no felt pain or fear during the insertion procedure. Almost all women who reported that the
rods were recognized by others in their arms (n=139) indicated that they were not annoyed
because of that. About 90 percent of women who were still using NORPLANT® intend to continue
NORPLANT® use to the end of the five-year duration. Almost two-thirds (61%) of all women
stated that they would recommend NORPLANT® to others. However, women who discontinued
NORPLANT® use (n=103) were less satisfied with the method. Only 42 percent of this group
reported that they were comfortable with NORPLANT® use and 28 percent said that they will
recommend NORPLANT® to others.
The study raised a number of recommendations. They addressed issues related to quality of care,
program sustainability and the ability of MOHP MIS to track and locate women eligible for
removal, including:
1.

Provide further training to service providers involved in NORPLANT® service provision.
Assessment of the specific training needs for quality NORPLANT® service provision is
needed.

2.

Promote accessibility to removal services and quality of these services.

3.

Develop adequate client follow-up systems to contact clients eligible for removal

4.

Develop an integrated quality oriented monitoring and evaluation system for NORPLANT®
service delivery sites.

5.

Reconsider the decision to provide NORPLANT® free of charge, in view of the findings on
women’s readiness to pay for NORPLANT® among the majority of women who received a
free method to promote NORPLANT® program sustainability.

6.

Develop appropriate mechanisms to promote central MIS capacity to locate and track
women to ensure that women have NORPLANT® removed or replaced when they become
no longer effective.
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BACKGROUND
There have been two sets of pre-introductory clinical trials of NORPLANT® implants in Egypt. The
Rockefeller Foundation and the Population Council supported the first trial in the early 1980s and
the Egyptian Fertility Care Society (EFCS), with support from the United States Agency for
International Development (USAID) and technical assistance from Family Health International
(FHI), conducted the second clinical trial in 1988. Physicians from five university hospitals in
Egypt provided NORPLANT® implants to 1,536 women during the period 1988-94. An
acceptability study (EFCS 1995) indicated that 93 percent
of the NORPLANT® clients surveyed were satisfied with
the method. Based on the positive experience gained
through these clinical trials, the Ministry of Health and
Population’s (MOHP) Central Administration for Family
Planning decided to proceed with the development of the
NORPLANT® Introductory Program and produced a
strategy and regulations for NORPLANT® service
provision. This provided guidelines for expanding the use
of NORPLANT® beyond the university hospital
environment of the clinical trials.
In November 1994 a task force was created that designed
the NORPLANT® Introduction Program. The original plan for the Program included two elements.
The first element was a broad geographic (horizontal) introduction of NORPLANT® that would
offer leading OB/GYN specialists throughout Egypt experience in providing this new contraceptive.
The second element was the vertical introduction of NORPLANT® in two governorates designed to
include more types of health facilities. The Program began in November 1995 when NORPLANT®
service provision was re-introduced in the five university hospitals that were included in the clinical
trials. NORPLANT® service was then introduced to more university hospitals and teaching
hospitals. In November 1996 the task force decided to expand NORPLANT® services to selected
urban MOHP sites and to modify the original plan for expanding NORPLANT® services. The
revised plan added the use of mobile teams, consisting of one physician and one nurse from
university or teaching hospitals. These mobile teams visited MOHP health facilities according to
predetermined schedules to provide one-day NORPLANT® services.
As of April 2000, NORPLANT® services have been provided in 11 university hospitals, 8 teaching
hospitals and 93 MOHP health facilities. The mobile teams provided NORPLANT® insertions free
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of charge. However, insertions done through university and teaching hospitals as well as at the
MOHP health facilities were provided for a fee (average LE 20). In mid-August 1999 the MOHP
decided to provide NORPLANT® free of charge at all MOHP health facilities. This decision has
substantially increased demand for NORPLANT® insertions at these sites.
There are several critical elements to providing high quality NORPLANT® services, including the
following:
•

the completeness of client records at the service delivery sites

•

the maintenance and linkage of local and central level registries of users

•

the capacity of local facilities to track and locate women who fail to return for removal, and
providers’ technical knowledge and attitudes about providing NORPLANT®

The MOHP and FRONTIERS began discussing the need for investigating these service delivery
aspects in 1999. From those consultations this study emerged.

STUDY OBJECTIVES
Long-term Objective
This study will help ensure that providers offer NORPLANT® in a balanced and culturally sensitive
way with proper attention to safety and quality issues, and the needs of users.
Immediate Objectives
The study has the following short-term objectives:
1. To assess the completeness and accuracy of the NORPLANT® central level management
information system (MIS) and client record cards, specifically related to the ability of the
NORPLANT® program to ensure the timely removal of expired NORPLANT® implants.
2. To identify factors influencing provider attitudes and motivation to provide NORPLANT®
services.
3. To develop an understanding of NORPLANT® users’ perspectives of the method, including
their satisfaction with the services they have received and their knowledge about the need
for timely removal.

STUDY DESIGN
The study employed an observational cross-sectional analysis of settings where NORPLANT®
services are currently provided. NORPLANT® providers (physicians and nurses) were interviewed,
at the facility where they work. In addition two categories of NORPLANT® users were requested
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to give consent for interviews:
1. Women who came to the study sites during the data collection period to have NORPLANT®
inserted or to receive follow-up services within one month of insertion. This group was
requested to consent to exit interviews.
2. Women who began NORPLANT® use between 1-4 years ago. These women were
identified by their medical records and were contacted at their homes by the health care
providers to ascertain if they would agree to an interview at the clinic or their home. An
abbreviated audit of the client record system at selected facilities and an audit of the central
level MOHP MIS of NORPLANT® users were conducted.

Study Instruments and Research Methods
The study employed 4 types of data collection instruments and 2 types of research methods.
1. Record system audit
The study compared information on clients obtained from the clinics’ client records (in clinic
registers and logbooks) to the actual client records available at the MOHP MIS central level to
assess the completeness of the recording system, and to check if information on NORPLANT®
clients recorded in the health facility logbook was also included in the central level MIS. A
review of the accuracy of the information was also conducted for client records that existed in
both the clinic and the central MIS.
2. Provider interviews
A standardized questionnaire was produced for use with all consenting physicians and nurses
who provided NORPLANT® services at the study sites, and who were available during the data
collection period.
3. Exit interviews
Standardized interviews were conducted with consenting women who had just received
NORPLANT® insertion at the study sites. Interviews were also conducted with women who
came to the clinic for a follow-up visit after one month of insertion and had just received
services and counseling. This group of women will be referred to as “new users” in the study
findings sections.
4. Home interviews
Follow-up interviews were conducted with randomly selected women who had NORPLANT®
inserted between 1-4 years ago at facilities included in the study sample. This group of women
will be referred to as “continuing users” in the study findings sections (keeping in mind that
some of these women discontinued NORPLANT® use later).
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Sampling Procedures
®

NORPLANT services are provided in
11 university hospitals, 8 teaching
hospitals and 93 MOHP hospitals. The
study was conducted in a purposively
chosen sample of approximately onethird of these sites to ensure selection
of the three types of health facilities
providing NORPLANT® services:
MOHP, university and teaching
hospitals. Table 1 shows the selected
study sites in the 15 governorates
covered. Twenty-nine clinics were
selected from MOHP, three clinics
from university hospitals and four
clinics from teaching hospitals,
yielding a total of 36 sites in the study.
Record system audit
Twenty client entries were selected
randomly from the MIS for each of the
study’s 36 clinics. These entries were
transcribed on the blank client record
sheets1 that MOHP clinics use to

Table 1: Sample Sites by Location and Type of Facility
Governorate
Clinic
Type
Cairo
El-Demerdash
University
El- Mataria
Teaching
Mansheit El- Bakry
MOHP
Dar El- Salam
MOHP
El- Monera(General)
MOHP
El- Zawia El- Hamraa.
MOHP
Alexandria
Atfal El- Raml
MOHP
Dar Ismail
MOHP
El – Amria
MOHP
Port Said
El- Nasr
MOHP
El- Manakh
MOHP
Dakahlia
El- Mansoura
University
Aga
MOHP
Dekarnes
MOHP
Qaloubia
Banha
Teaching
Kalub
MOHP
Dar El- Welada
MOHP
Menofia
Shebein El- Kom
Teaching
Kafr El Sheikh
Kafr El-Sheikh
MOHP
Kelein
MOHP
Behira
Kafr El- Dawar
MOHP
Ismailia
El- Kantara
MOHP
Beni Suef
Beni Suef(General)
MOHP
Naser
MOHP
Fayoum
Ebsheway
MOHP
Tameia
MOHP
Menya
Sozan Mobark Center
MOHP
El- Menya (General)
MOHP
Assuit
Assuit
University
Assuit (General)
MOHP
El- Badary
MOHP
Qena
Abou Manaa Bahari
MOHP
Nekada
MOHP
Souhag
Souhag
Teaching
Souhag (General)
MOHP
Dar El- Salam
MOHP
Total
36

record information for women who have had NORPLANT® inserted. Data collectors were
instructed to locate data from client record sheets from the clinic registers/logbooks. For some
clinics the total available MIS records were less than 20 cases. In these small caseload clinics all of
the available records were used. The information collected from the clinics’ registers/logbook was
then compared with the information retrieved from the central MIS. Discrepancies were detected
(both completely missing cases and cases with non-matching information). A form was developed
that used an ordinal ranking of the fit between these two independent data sources and also of the
degree of completeness of the information. The ranking classified each data item as either 0 (no fit)
or 1 (perfect fit).

1

The client record sheet includes data on client’s name, some socio-demographic data (e.g., age, parity, education), date
of insertion, client’s address and husband name, name and address of one of the client’s relatives (not residing at the
same household), name of the physician who inserted NORPLANT®, expected date of removal, actual removal date and
reasons for removal. This sheet included 19 data items.
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Client follow-up card audit
During home interviews, each woman was asked if she has received a follow-up card from the
clinic. The information recorded on the card (if available) was copied on a form that was designed
for this purpose. The corresponding information from the clinic’s registers was also copied on the
same form. Information of these two sources was then matched in the office.
Monthly caseload and staffing information
A clinic form was designed to collect information from each of the study sites on the number and
types of service providers, the number of service providers who received training on NORPLANT®
insertion/removal, the year that NORPLANT® services were first provided, and the availability of
client follow-up services and other information related to NORPLANT® insertion and removal.
This form also abstracted data on NORPLANT® monthly caseload (insertion/removal) from each
clinic’s logbook for the 14 month period of August 1999-September 2000.
Home interviews of continuing users
Women eligible for home interviews were defined as those women who had NORPLANT® inserted
between 1 to 4 years ago. Clinic staff (usually nurses) in each of the study’s 36 sites were instructed
in systematic random selection procedures
to identify 18 client names from the clinic
register/ logbook for a total of 648. Special
forms were developed for recording
locator information, (the woman’s name,
her husband’s name and her address). Due
to inaccuracies in addresses and other
difficulties in locating the woman (even if

Table 2: Sampling Results for the Home Interviews with
Continuing Users of NORPLANT®
Outcome of interview
Percent
N
Completed
55.5
624
Address not located
37.2
419
Address located but no woman with
2.7
30
same name
Refused
0.2
2
Other*
4.4
50
Total
100.0
1,125
*women who received NORPLANT® service in other governorates
through mobile teams and were registered in the clinics’ logbooks

the address was correct), additional women were randomly selected to reach the target number of
home interviews. A total of 624 home interviews were completed out of 1,125 randomly selected
clients (55 percent) (see Table 2). The majority of clients included in the sample of home interviews
were women who had NORPLANT® inserted less than two years ago (because of the lack of
information in clinic registers on women who had NORPLANT® inserted more than two years ago).
However, due to incomplete logbooks, missing addresses, and the unavailability of logbooks in
some clinics for more than two years, it was necessary to include in this sample some women who
had NORPLANT® inserted less than 12 months ago to achieve the target sample. For this latter
group (n= 174), the mean duration of insertion is 8.4 months and the median is 10 months.
Clinic staff (usually the Raida or the nurse) approached the women selected for home interviews to
obtain their informed consent. Consenting women were given the option of either visiting the health
facility to meet with the female interviewer or conducting the interview at home, at their
convenience.
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Exit Interviews
All eligible NORPLANT® users were contacted after they had received services and were asked to
give consent for an interview. This process continued in each clinic until 20 clients were
interviewed.

Data Collection Procedures
Pre-test of the study instruments
The study instruments were pre-tested in five clinics that were not included in the study sites. The
pre-test training lasted for three days. Two teams were involved in the pre-test activities for one
week. Each team consisted of five interviewers and two supervisors. Review sessions were held
with the interviewers and supervisors to get their feedback. Necessary changes were made to the
study instruments by El-Zanaty & Associates and the Population Council staff.
Training of data collectors
Data collectors and supervisors participated in an intensive one-week training workshop that started
on September 30, 2000. Approximately 40 female interviewers and 15 male supervisors attended
®

the training. The training included information on the NORPLANT program in Egypt and
intensive training on how to fill out the study instruments using appropriate visual aids. The
principal investigator and research coordinator led training sessions over four days. The last two
days of the training workshop
included role plays and a quiz.
Finally, 36 interviewers and 13
supervisors with the best
performance were selected to
participate in the field data
collection activities.
Field work
Thirteen data collection teams,
each consisting of one male
supervisor and two to four female interviewers (based on the number of clinics assigned to each
team) were formed. Each team was assigned to work in one or two governorates. One interviewer
was assigned to a study site. The interviewer was responsible for conducting client exit interviews,
home interviews (for clients who received NORPLANT® service at this clinic) and provider
interviews. In addition, the interviewer was responsible for completing the information sheets on
client cards. Based on client caseload information and the target number of interviews, each
interviewer was instructed to stay between two to four weeks at the clinic to collect data needed.
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The supervisor was responsible for organizing the teamwork; field editing of the completed forms
and making sure that the target sample was achieved. In addition, the supervisor was responsible for
completing the clinic form. Due to variability in caseload between clinics, gathering the target
number of 20 exit interviews for some clinics was difficult. Therefore, data collection was extended
in some clinics for an additional week.
Quality control measures were applied throughout the data collection period including the close
supervision of data collection procedures. The principle investigator, research coordinator,
fieldwork coordinator and

Table 3: Sampling Results (completed forms) by Type of Health Facility

Population Council staff made
regular visits to the study sites to
observe the field work and
monitor informed consent
procedures. In addition, ten
percent of the study sites were
randomly selected to compare

Type of Hospital
Exit interviews
Home interviews
Physicians interviews
Nurses interviews
MIS client entries checked*
Client’s card

MOHP University
572
500
47
50
334
189

83
54
11
6
52
24

Teaching

Total

85
70
8
8
73
63

740
624
66
64
460
276

*This number represents matched clients’ records (available in both clinic registers and
MIS). However, the overall number of MIS client entries checked was 720

the data collected with the clinic’s records. Data collection activities began in the second week of
October 2000 and lasted for five weeks. Table 3 shows the number of study instruments completed
by type of health facility.

FINDINGS
Clinics Characteristics
Table 4 presents data on selected characteristics of the study sites by type of facility. The clinics
providing NORPLANT® insertion services have on average 4.3 physicians providing family
planning services,
and close to half
are trained on
NORPLANT®
insertion (2.3
physician). The
number of

Table 4: Study Sites by Type and Selected Characteristics (n=36 clinics)
Characteristics
MOHP University Teaching
(n=29)
(n=3)
(n=4)
Mean No. of physicians
4.2
7.0
3.0
Mean No. of physicians trained on
1.9
6.7
2.3
NORPLANT® Insertion
Mean No. of physicians trained on
1.7
6.7
2.3
®
NORPLANT removal
Mean No. of family planning nurses
2.5
4.3
2.0
Percent of sites that provide removal
69.0
100
100
services

Total
(n=36)
4.3
2.3
2.2
2.6
75.0

Source: Clinic information form

physicians who
received training on NORPLANT® removal is slightly less (on average 2.2 physician). The average
number of nurses involved in family planning service provision (2.6) is lower than the number of
physicians. The mean number of physicians and nurses providing NORPLANT® services at the
university hospitals is about double the mean number of the same service categories at MOHP
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clinics and teaching hospitals. It may be noted here that, based on available information on number
of physicians trained on NORPLANT® insertion, it was found that mean number of insertions
during the month of September, 2000 per physician at MOHP clinics (7.5 insertions) was much
higher than the comparable mean for physician at university hospitals (3.2) or teaching hospitals
(3.0). Removal service is not available in all MOHP clinics (69 percent only), but available in all
university and teaching hospitals.
®

Figure 1 shows the trend of mean monthly NORPLANT caseload per clinic during the period
August 1999 - September 2000 for both insertions and removals. In general, for all the period
shown, and all clinics the
monthly mean number of

Figure 1: Average Monthly Number of
NORPLANT® Insertions and Removals

insertions per clinic is 11.3
and the median is 9.5 with a
range of insertions of 1.8 –
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40.1. Also, the monthly
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mean number of removals is

12
9

1.2 and the median is 0.1,
with a range of removals of
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by type, the findings
indicated that for all the
period shown, the monthly
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14.72

13.42

11.75

12.58

11.20
10.89

10.14
8.97

9.78

9.11

9.61

3
0
Au

g1

0.64 0.72

0.67 0.72

0.53

0.67 1.42

1.22

8.46

8.42

6
1.36

1.28 1.33

7.97

1.83

1.54 1.69

0
9
9
9
0
0
0
0
0
0
9
0
0
99
00
99
99
99
00
00
00
00
00
00
00
00
99
19
t 1 ov 1
r2
r2
c 1 Ja n 2
y 2 u n e 2 Ju l 2 u g 2 e p t 2
b2
pt
Oc
De
Ap
Ma
Fe
A
N
Ma
J
Se
S

Insertion

Removal

Source: Clinic Logbooks (n=36 clinics)

and removals per MOHP clinic is 10.9 and 0.2 respectively. For the university hospital, the
comparable means are 12.5 and 6.9, and for the teaching hospital 12.7 and 4.0, respectively.

Selected Socio-demographic Characteristics of Physicians
Table 5 presents the findings on socio-demographic characteristics of the physicians who provide
NORPLANT® services in the study sites. The majority of the physicians are male (62 percent) and
more than one-half of them are 40 years old or more (mean age is about 41 years). More than 90
percent of the physicians have attained post-graduate degrees (diploma, master or doctorate degree).
In fact, all the university and teaching hospital physicians have attained post-graduate degrees,
®

indicating a high education level overall among physicians who provide NORPLANT services.
On average university hospital physicians have worked about six years in providing NORPLANT®
services compared to about three years for teaching hospitals physicians and a year and half for
MOHP physicians.
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Table 5: Selected Socio-Demographic Characteristics of Physicians who Provide
NORPLANT® (n=66)
Characteristics
MOHP
University
Teaching
(n=47)
(n=11)
(n=8)
Sex
Male
53.2
100
63.0
Female
46.8
0.0
37.0
Age
Less than 30
2.1
18.2
0.0
30-39
29.8
72.8
25.0
40+
68.1
9.0
75.0
mean age
41.7
33.6
44.0
Education (highest degree attained)
University degree
10.6
0.0
0.0
Diploma / Master / Ph.D.
89.4
100.0
100.0
Experience with NORPLANT® service
provision
Mean no. of years working in NORPLANT®
1.4
5.6
2.9
service provision
Received training in NORPLANT®
insertion/removal? (yes)
93.6
100.0
87.5
Need additional training in insertion? (yes)
27.2
9.1
12.5
Need additional training in removal? (yes)
61.7
18.2
50.0
Source: physician interview

Total
(n=66)
62.1
37.9
4.5
36.4
59.1
40.6
7.5
92.5
2.3
93.9
22.7
53.0

Physicians were asked about the training they received in family planning and reproductive health
as well as in NORPLANT® insertion and removal. They were also asked if they thought that the
training they received in NORPLANT® insertion and removal was sufficient. Almost all the
physicians indicated that they received training in family planning and reproductive health areas.
Approximately 94 percent of the physicians who provide NORPLANT® services have attended
training courses on the insertion and removal of NORPLANT® but physicians in teaching hospitals
were less likely to be fully trained. Overall about one-half of the physicians who provide
NORPLANT® reported a felt need for additional training in NORPLANT® removal.

Selected Socio-Demographic Characteristics of Nurses
Table 6 presents data on selected socio-demographic characteristics of nurses. About two-thirds of
the nurses are less than 40 years old, with a mean age of 34 years. The majority of them received
nursing school level (88 percent), which requires a minimum of 12 years of schooling. Overall,
nurses reported working in NORPLANT® service provision for an average of almost two and onehalf years. However, university hospital nurses had more experience in NORPLANT® service
provision (mean number of years is 8.3). These nurses are also relatively older and more qualified
compared to MOHP and teaching hospitals nurses. Almost all of the nurses have received training
in family planning and the large majority (79 percent) have received training in NORPLANT®
service provision.
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Table 6: Selected socio-demographic characteristics of nurses (n=64)
Characteristics

MOHP
(n=50)

Age
Less than 25
25-30
30-39
40+
Mean age
Education (highest degree attained)
Nursing school
Nursing school + one year specialization
Years working in NORPLANT® service
provision
Less than one year
1
2
3
4+
Mean
Received training in family planning and
reproductive health?
Yes
Number of training workshops attended
1-2
3
4+
Mean
Topics of training workshops
FP methods
NORPLANT®
Reproductive Health
TOT
Registration

Percent
University
Teaching
(n=6)
(n=8)

Total
(n=64)

20.0
22.0
26.0
32.0
33.5

0.0
16.7
16.7
66.7
39.7

12.5
25.0
12.5
50.0
35.4

17.2
21.9
23.4
37.5
34.3

94.0
6.0

66.7
33.3

62.5
37.5

87.5
12.5

26.0
30.0
8.0
26.0
10.0
1.6

0.0
0.0
16.7
0.0
83.3
8.3

0.0
0.0
25.0
62.5
12.5
2.9

20.3
23.4
10.9
28.1
17.3
2.4

98.0

100.0

100.0

98.4

44.9
26.5
28.6
3.0

0.0
16.7
83.3
4.8

25.0
75.0
0.0
2.6

28.1
31.7
30.2
3.1

100.0
75.5
55.1
28.6
8.2

100.0
100.0
100.0
83.3
50.0

100.0
87.5
75.0
0.0
0.0

100.0
79.4
61.9
30.2
11.1

Source: nurse interview

Selected Demographic and Socio-economic Characteristics of NORPLANT® Users
Table 7 presents data on selected demographic and socio-economic characteristics of new and
continuing users of NORPLANT® obtained through exit interviews and home visits (respectively).
The data show that new users are on average younger (mean age = 31.4 years) than continuing users
(mean age = 34.3 years) and the difference is significant (p<0.05). Both groups of women had
nearly the same mean number of living children (slightly more than four). On average, the mean age
of youngest child was 2.8 years for new users which is significantly lower than the mean age of 4.8
years for continuing users (the difference is significant, p<0.05).
It should be noted that the study findings reflected a higher percentage of women who use
NORPLANT® for spacing purposes among new users (14 percent) than continuing users (only 9
percent) (not shown in the table). This may explain the difference in the mean age of youngest
child. In addition, the mean age of youngest child for the continuing users refers to date of interview
rather than date of insertion.
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It is interesting to note that
continuing users were on
average better educated,
married to husbands who
were also relatively better
educated and were more
likely to work for cash
(however, only difference in
work status is significant,
p<0.05). The results from the
Standard of Living Index
(SLI) further corroborate
this finding (see the bottom
of Table 7 for description of
constructing the SLI index).
The mean SLI value for
continuing users is 12.5
compared to 11.9 among new
users (the difference is
significant, p<0.05). This
finding may reflect the
influence of making
NORPLANT® free of charge
among women belonging to
lower socio-economic levels.

Client Record System
Audit
The study compared
information on clients

Table 7: Selected Socio-Demographic and Economic Characteristics of New
and Continuing Users of NORPLANT®
Percent
Characteristics
New users
Continuing users
(n=740)
(n=624)
Age1
<25
14.2
3.8
25-34
50.5
45.5
35+
35.3
50.6
Mean age
31.4
34.3
Living children
1
2.1
1.1
2-3
43.6
35.9
4+
54.3
63.0
Mean
4.1
4.2
Age of youngest child1
Less than a year
23.7
4.8
1
14.2
13.0
2
13.4
16.0
3+
48.7
66.2
Mean
2.8
4.8
Education
Illiterate
52.0
52.5
Read and write
12.7
11.6
Primary/preparatory
16.6
14.0
Secondary and above
18.7
22.0
Work status1
Not working
84.2
76.3
Working/no cash
4.6
6.3
Working for cash
11.2
17.5
Husband education
Illiterate
33.6
30.0
Read and write
16.1
17.0
Primary/preparatory
18.5
20.8
Secondary and above
31.8
32.2
Standard of Living Index (SLI) 1,2
Low (2-10)
31.2
20.7
Medium (11-13)
36.5
40.4
High (14-25)
32.3
38.9
Mean SLI
11.9
12.5
Source: client exit and home interviews
1. Differences are significant (P<0.05)
2. A composite index for socio-economic status of the household. It includes a set of
variables related to housing conditions and ownership of consumer durables of the
woman’s household. The housing conditions included in the index and their scoring are
as follows: one point for each room in the household; one point for piped drinking water,
modern flush toilet, electricity and a cement/ cement tile floor; and two points if the floor
material was wood parquets, ceramic tiles, marble or wall-to-wall carpet. In addition, one
point was given for ownership of each of the following items: a radio with cassette
recorder; a black and white television; a color television; a video; a telephone; an electric
fan; a water heater, a refrigerator, a washing machine, a bicycle, a private car/
motorcycle, transport equipment, farm or other land and livestock. Based on data of exit
and home interviews, the value of this index ranged between 2-25

obtained from the clinics’ client records (in clinic registries and log books) to the actual client
records available at the MOHP MIS central level to assess the reliability and completeness of the
recording system. Table 8 summarizes these findings. Records that existed in both clinic registers
and MIS (regardless of the accuracy of client’s information) represented about two-thirds (64%) of
the cases. One-third of clients’ records were available in clinics’ registers but not in the MIS. The
majority of this category was found at MOHP facilities. Three percent of the clients records were
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available in the central MIS
but not in the clinics, (about
13 percent of university
hospitals’ records fall in this

Table 8: Matching Client Records at MIS Central Level and Clinic Level
Percent
MOHP
University
Teaching
Total
(n=580)
(n=60)
(n=80)
(n=720)
Client records exist in
clinics and MIS
57.9
86.7
91.3
64.0
Client records exist in
clinics but not in MIS

40.0

0.0

7.5

33.0

records information between

Client records exist in
MIS but not in clinics

2.1

13.3

1.2

3.0

clinic and central MIS

Source: central/MIS and clinic registers

category).
Accuracy of client

A review of accuracy of the information was conducted for client records that existed in both the
clinic and the central MIS (n=460). Each client record included 19 information items. These
indicators were compared
in the two sources
(clinics’ registers and
MIS), and each item was
given a score of 1 in case

Figure 2: Agreement on Key Indicators Between
Client Record Information at MIS Central Level
and Clinic Level
Degree of agreement*
0.95
1

of “perfect fit” and 0 in

0.8

case of “no fit.” Figure 2

0.6

presents the findings of

0.4

these comparisons for
only selected information
items. The mean of the
degree of concordance
between the two sources

0.67
0.48

0.40
0.25

0.2
0

Insertion date

Insertion
Last FP
Due romoval
complications method used
date

Woman's
address

* 1 for perfectly matched information (complete agreement) and 0 for no match (complete
disagreement)

Source: clinics registers and central MIS (n=460 records)

of data is high for the
insertion date (0.95), moderate for the insertion complications (0.67), low for removal date (0.4)
and last family planning used (0.48), and very low for woman’s address (0.25).
Accuracy of the clients’ addresses
Each facility that provides NORPLANT® should keep complete and correct information about the
clients’ addresses and the addresses of one of their relatives in order to ensure follow-up care,
including removal of the implants. The availability of this information is critical for clients who fail
to return to clinics for removal at the end of NORPLANT® use duration. Table 2 (presented earlier)
indicates that only about 56 percent of the continuing users selected at random for the home
interview were actually reached using the locator information on the client records. An additional
37 percent of NORPLANT® clients could not be located because their addresses were incomplete.
Furthermore, in the majority of clients’ records information on the relative’s address was not
collected. In only 3 percent of the cases the address was complete and correct but it was not
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possible to interview the women. This represents cases that implicitly refused to give consent for
follow-up contact, and it is noted to be a very small proportion of the total sample.
Existence of the clients’ cards
The MOHP Systems Development
Project established a follow-up
system for all family planning
clients, including NORPLANT®
users. Client who receive a family
planning method are given a card
to record the dates of follow-up
visits. To assess the accuracy of
information of the client follow-up

Table 9: Client Follow-up Cards: Receipt by NORPLANT® Users
and Agreement of Information with Clinic Records
Item
Received a card from the clinic? (n=624)
Yes, and I still keep it
Yes, but later was lost
No
Matched Items (agreement)*, (n=267)
Client serial number
Year of insertion
First follow up scheduled visit date
First follow up actual visit date

Percent
45
40
15
0.88
0.98
0.60
0.71

Source: home interviews and clinics’ logbooks
* perfect agreement = 1.00, perfect disagreement = 0.00

®

card for NORPLANT users, interviewers were instructed to ask each continuing user during the
home interview if she was given this card. If she answered yes, the interviewer requested to see the
card and to transcribe all the information recorded on it to a form designed for this purpose. Field
supervisors recorded the comparable information for the same woman from the clinic register on the
same form. Information

Figure 3: Decision Making Roles on FP Methods
as Reported by NORPLANT® Physicians

from both sources was
then compared and
discrepancies identified
(Table 9). The table shows

Who decides about the appropriate FP method?

that 45 percent of

Woman
12%

®

continuing NORPLANT

users received a card and
were still keeping it. Twofifths (40%) received the
follow-up card but it was
later lost. In 15 percent of
cases, women said that

I explain all
methods &
the woman
makes
choice
42%

I make the
decision,
depending
on woman's
health
46%

Source: physician interview (n=66)

they did not receive a card. Cases in which the card was available also indicated some discrepancies
in accuracy of information recorded on the card, but overall the information on the client card
corresponded with the clinic records particularly on the year of insertion.

An Assessment of the Egyptian NORPLANT® Program

13

Health Care Providers’ Attitudes and Technical Knowledge
Physicians were asked
about who decides which

Figure 4: What are the Advantages of NORPLANT®?

family planning method
Percent of physicians indicating advantage

is most appropriate for a

Safe/effective method

woman to use (Figure 3).

61

Women can easily get pregnant after removal

Two-fifths of the

32

Long-acting method

physicians (42%)

71

Woman doesn't need to remember it

indicated that they

51

Contains single hormone

36

Easily inserted and removed

explain to the client all

9

Less side-effects

family planning methods

21

Other*

18

and talk with them about

0

their health conditions,

20

40

60

80

*includes does not need vaginal examination, does not affect breastfeeding,
does not interrupt intercourse, physician dependent

and then the woman

Source: physician interview (n=66)

makes the choice. An
additional 12 percent stated that the woman makes the choice. Taken together these findings
indicate that slightly over one-half of the physicians report some degree of choice-making authority
rests with the client. Unfortunately, the remaining 46% of the physicians claim full responsibility
for selecting the client’s

Figure 5: What are the Disadvantages of
NORPLANT®?

family planning method.
Physicians were asked

Percent of physicians indicating disadvantage

about their views about
®

Nausea and blurring of vision

NORPLANT advantages
and disadvantages. The

®

is a long-acting method
(reported by 71 percent)
effective method (61

12
36
27

Severe bleeding

frequently mentioned

and that it is a safe and

9

Severe headache

advantages most
were that NORPLANT

5

Weight gain
Surgical procedure
Difficulty of removal

42

Menstrual cycle disturbance
Pain at site of insertion

62
14

None

3

Other*

15
0

10

20

30

40

50
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70

*Includes: affects libido, visible in arm, causes illness, affects breastfeeding if
used before 6 months after delivery, possibility to select inappropriate candidates
Source: physician interview (n=66)

percent) (Figure 4). About one-half of physicians mentioned that women do not need to remember
doing anything to avoid pregnancy, like taking a pill daily. The most frequently reported
disadvantage of NORPLANT® is that it causes menstrual cycle disturbance (reported by 62% of
physicians) (see Figure 5). The next most frequently mentioned disadvantage is that it sometimes
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causes severe bleeding (42%), followed by difficulty of removal (36%). Other disadvantages
mentioned were NORPLANT® causes severe headache (27%), pain at site of insertion (14%),
weight gain (9%) and that its insertion and removal required a surgical procedure (12%). In a
separate question (results not shown in Figure 5), physicians were asked about the side effects of
®

NORPLANT . The responses indicate a moderate level of awareness or knowledge. The majority
of them mentioned menstrual cycle disturbances (86%). About one-half mentioned headache
(60%), weight gain (50%) and bleeding (49%).
Both physicians and nurses
were asked about the type

Figure 6: What is the Information you Provide to
Women who Require a NORPLANT®?

of information they provide
to women who come to

Insertion procedures
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®

percent) mentioned the number of NORPLANT rods and insertion procedure (64 and 53 percent).
Only 24% of the physicians mentioned removal procedures.
Figure 7 presents the
results on physicians’

Figure 7 : What are the Contraindications of
NORPLANT® Use?

knowledge about the
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®

NORPLANT use. These
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this issue. With the exception to the presence of tumors of the breast (cited by 53% of the
physicians) and experience of high/low blood pressure (cited by 61% of the physicians) other
causes were reported by a low percentage of physicians, and inaccurate or false contraindications
were provided.

Selected Aspects of Service Provision and Related Performance Appraisal
Experience with

Figure 8: Difficulties in Removal of NORPLANT®
Implants

®

NORPLANT removal
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removed NORPLANT

®

The rod was broken 18%

(n=51) were asked if
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difficulties in

Fibrosis around implanted capsules 9%
Unclear site of implanted capsules 36%

Yes

No

43 %
n=22

57 %
n=29

Difficulty of removal in one session 32%

®

NORPLANT removal.

Unavailability of equipment needed 4%
Incorrect insertion 9%

About two-fifths (43%)
responded affirmatively
(Figure 8). The most
frequent problems met

Type of removal problems
faced (n=22)

Have you faced any removal
problems?
(n=51)
Source: physician interview

were that the site of implanted capsules was not clear (36%) and difficulty of removing all rods in
one session (32%). The latter difficulty implies that more than one visit to the clinic was needed by
the woman to completely
remove which is a cause
for concern. Other
difficulties faced were
that the rod was broken
during removal (18%)
and incorrect insertion of
the capsules and the
presence of fibrosis
around implanted
capsules (reported each

Figure 9: What are the Infection Control
Procedures that Should be Followed During
NORPLANT® Insertion/Removal?
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Woman sterilization
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®

An important aspect of safe provision of NORPLANT services is care given to infection control
measures during insertion and removal procedures. Figure 9 presents information on how both
physicians and nurses
reported they manage

Figure 10: Follow-up Care Provided to Women who
Inserted NORPLANT®

infection prevention. Health

Send
Raida
to client
11%

care providers placed high
importance on equipment
sterilization as well as
physician and woman sterile

Nothing
80%

No
15%
Yes
85%

practices. Other infection

Other
9%
What happens if the woman
doesn ’t visit the clinic for
due follow -up visit

control procedures reported
Is there a follow -up system
at this clinic for women who
inserted Norplant?

by at least two-thirds of the
study’s physicians and nurses

(n=66)

(n=54)

included sterilization of the
Source: physician interview

site of insertion, nurse

sterilization and hand washing. Patterns of responses given on infection control procedures seem to
be more or less the same for both physicians and nurses.
®

Since NORPLANT is a provider dependent method, it is important that the health care system
®

ensure health care providers follow up to ensure that users have NORPLANT removed or replaced
when the implants becomes no longer effective. Figure 10 shows that the majority of physicians
indicated that their clinics
maintain a follow-up system
for women who inserted
NORPLANT® In fact, this

Figure 11: NORPLANT® Shortages
Do you face any shortage of
®
NORPLANT supplies?

®
- -out,
In case of NORPLANT stock
what do you do for the woman who
®
wants NORPLANT ?

system primarily involves the
use of follow-up cards with
scheduled dates for follow-up
visits to the clinics (which

Refer her to another clinic 14%
Ask her to use another method instead 12%

No
47 %

Give her another method until NORPLANT
becomes available 42%

Yes
53 %

40% of the continuing users

Ask her to come another day 24%

reported losing, Table 9).

Other 8%

There appears to be an overreliance on this system, when

(n=66)

(n=35)

Source: physician interview

physicians were asked about
what happens if a woman doesn’t visit the clinic for her due follow-up visit, about four-fifths of
physicians (80%) reported that there is no mechanism in place to do home visits for those women.
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®

This means that women who may forget due removal date/end of NORPLANT effective use
duration will not be contacted by clinic staff to be advised for removal. About one-tenth of
physicians, however, reported that usually the clinic sends a Raida (community outreach worker) to
the woman’s home to remind her about the due follow-up visit.
®

Figure 11 presents data on the availability of NORPLANT supplies as reported by physicians.
About one-half of physicians indicated that they sometimes experience a shortage of NORPLANT

®

supplies. When asked what they do in this situation if a woman requests NORPLANT® insertion,
®

about two-fifths reported that they give the woman another method until NORPLANT supplies
become available. An additional 12 percent said they ask the woman to use another method instead
®

of NORPLANT . About one-fourth of the physicians reported that they ask the woman to come to
®

the clinic later (another day) when NORPLANT will be available. About 14% of the physicians,
®

however, reported that they refer the woman to another clinic, if they think NORPLANT supplies
are available there.
Promotion of NORPLANT

®

®

This study examined how NORPLANT are promoted or encouraged (see Figure 12). Service
providers were asked a set of questions on whether or not they receive cash incentives for
®

NORPLANT insertion and the level of these incentives. A small percentage of physicians and
nurses (23 and 13 percent, respectively) reported that they receive cash incentives for
®

NORPLANT insertion. Among this group, about one-half of physicians and one-third of nurses
think that the level of cash
incentives received is
appropriate. For other service

Figure 12: Mechanisms for the Promotion of
NORPLANT® Services
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level of incentives is not
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about their perception of the
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The average cash incentive
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physicians for physicians was
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Source: physician and nurse interviews

With regard to nurses, they proposed an average incentive payment for physicians of LE 150 and
An Assessment of the Egyptian NORPLANT® Program

18

for nurses LE 84 (not shown). In general, for all physicians and nurses interviewed, the majority
®

report that monetary incentives could contribute to increase NORPLANT insertion caseload (80%
of physicians and 67% of nurses).
It may be noted here that, according to MOHP policy for incentives, women requesting
®

NORPLANT insertion were originally asked to pay LE 20 for the method. This amount was
®

distributed among service providers working in NORPLANT services. However, as indicated
®

earlier, MOHP is now offering NORPLANT free of charge, but still the same amount for each
®

NORPLANT set inserted (LE 20) is distributed to service providers as follows: 3 percent for
administrative staff, and the rest is divided among 60 percent for physicians and 40 percent for
nurses and Raida Rifia (social workers).

Figure 13: What are the Five most Important
Problems in NORPLANT® Service Provision*?
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Finally, physicians and nurses were asked about their views about the five most important problems
®

in NORPLANT service provision program. Figure 13 shows their responses. Both physicians and
nurses think that the most
important problem is the lack of
media advertising about
®

NORPLANT . Though

Table 10: Source of Information on NORPLANT® among New Users
(n=740)
Percent
®
Did you know about NORPLANT before use?
Yes
93.6
Source of information
Physician/nurse
Mass media
Relatives
Friends/neighbors
Others

priorities given by physicians
®

and nurses on NORPLANT

program problems differed, the
type of problems reported were
more or less the same. Problems
reported included the need for
more training of service
®

providers, lack of NORPLANT

18.4
24.9
19.7
34.7
2.3

Did you know source of NORPLANT® before use?
Yes
Source known (n=675)
MOHP facility
University hospital
Teaching hospital
Other

91.2
79.9
19.7
10.5
9.9

Source: client exit interview

supplies, lack of equipment needed, and insufficient provider incentives.
®

Clients’ knowledge about NORPLANT and satisfaction with NORPLANT® services

Table 10 presents data on sources of information on NORPLANT® as reported by new users.
Almost all of the new users (94%) knew about NORPLANT® before they came to the clinic to have
it inserted. More than one-half knew about NORPLANT® through “word of mouth” (e.g., satisfied
relatives, friends or neighbors using NORPLANT®). Mass media was reported by about one-fourth
of the new users as their source of information. About 18% of the new users learned about
NORPLANT® first from the

Figure 14: Previous FP Method Used among New
NORPLANT® Users
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Other
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Want to
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Source: client exit interview
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All of the new
NORPLANT® users were

Figure 15: Factors Affecting the Decision to Accept
NORPLANT® Among New Users
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NORPLANT® (i.e., new

acceptors). The IUD and injectables were used each by about one-third of women before switching
to NORPLANT®. The pill was used by about one-fourth of women. As expected, method sideeffects were the major reason for discontinuing last method used before NORPLANT® (reported by
70% of the women). Other reported reasons for discontinuing last method included the need for a
more effective method (9%), method failure (6%) and that the woman wants to get pregnant (4%)
(Figure 14).
Figure 15 provides relevant
data on factors affecting the
decision to begin using
NORPLANT®. About

Figure 16: Information Given to New Clients by
Service Providers
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four-fifths (81%) of the
women indicated that they
came to the clinic with the
intention to use

63

Told about side -effects

39

Told about use duration

96

Told about insertion procedures

®

NORPLANT (i.e., already

53

Told about removal procedures

decided on the method to

11
0

be used). About two-thirds
(65%) of women said that

40

Told about NORPLANT advantages

20

40

60

80

100

Percent answering yes
Source: client exit interview (n=740)
(,

the physician advised them to use NORPLANT®. Only two-fifths (40%) of the women interviewed
reported that they received counseling on all family planning methods.
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As a following question on who finally made the choice for NORPLANT® method, the majority of
the new users (72%) stated that they themselves made the final choice and another 11% reported
that the physician and the woman jointly made the decision. These data indicate that women’s
informed choice was reasonably upheld (Figure 15).
This study also collected information on counseling and information given to clients by service
providers before and after NORPLANT® insertion. Figure 16 shows information given to new users
by service providers before the NORPLANT® insertion procedure. Almost all of the women (96%)
reported being told about the use duration of NORPLANT® (i.e., five years). About two-thirds were
told about NORPLANT® advantages and one-half were told about NORPLANT® insertion
procedures. Counseling on potential side-effects was provided to only 39% of the women. In fact,
during client exit interviews, most new users reported that physicians told them “if anything wrong
happened, return to the clinic,” without specifying the potential side-effects (not shown in the
figure). In addition, only 11% of the new users were told about NORPLANT® removal procedures
before having the implants inserted. This last point indicates a short-coming in the provision of preinsertion information.
All new users were asked to report on follow-up information given to them by service providers
after NORPLANT® insertion (Figure 17). The majority reported being told about the need for
follow-up visits (92%).
However, only 82%
reported that they received

Figure 17 : Follow-up Information Given to New
Acceptors after NORPLANT® Insertion
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This is a serious information gap that needs to be emphasized in provider training. Also, only about
two-fifths of clients were told that NORPLANT® could be removed before the due date for removal
if needed, and almost the same proportion of women were told about clinics that provide removal
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services. In addition, about 69% of women were advised what to do in case they experienced sideeffects (Figure 17).
The study examined the
satisfaction with the
NORPLANT® method and

Figure 18: Satisfaction with NORPLANT® Methods
and Services among New Clients
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Source: client exit interview (n=571, 168, 740, 740, 740, 268, 740 respectively)

18). Eighty-nine percent of the new users who received a free method reported that they would still
request NORPLANT® insertion if they were asked to pay for it. Seventy-six percent of the new
users who paid for the method reported that the payment made was reasonable (mean payment for
the method was LE 16.9). About two-thirds (67%) of the new users reported that they would
recommend NORPLANT®

Figure 19: Continuing Users Reports on Principal
Advantage and Disadvantage of NORPLANT®
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advantages and
disadvantages of NORPLANT® as reported by continuing users are shown in Figure 19. The two
most commonly cited advantages to NORPLANT® use are its long duration (36%) and fewer side
effects (24%). In fact some of the continuing users mentioned that they had tried some other family
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planning methods previously, but were not able to tolerate the side-effects. They felt that they had
less side-effects with NORPLANT® or side-effects that were more tolerable (not shown in Figure
19). An additional 12% of the continuing users reported the principal advantage was not having to
worry about remembering
to take a pill every day, or
an injectable every 3

Figure 20 : Principal Reason for Discontinuing Use
of NORPLANT® before 5 Years
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Source: home interviews n=103

about two-fifths (42%) of
the continuing users do not perceive any disadvantage for NORPLANT® (Figure 19). The most
frequently reported disadvantage was that NORPLANT® causes menstrual cycle disturbance (cited
by 26%). Other reported disadvantages included headache, weight gain and pain in body (reported
each by about 6%).

Women who had NORPLANT® removed before 5 years of use (17 percent) were asked to give the
principal reasons for early removal (Figure 20). Experiencing bleeding was the main cause of
dissatisfaction with the method that led to early removal (reported by about one-half of women who
stopped using NORPLANT® An additional one-fourth mentioned that they removed NORPLANT®
because of its other side-effects. Some women (9%) removed NORPLANT® due to reasons not
related to the method, for example, they wanted to become pregnant (5%) or infrequent sex (4%).
Women who had NORPLANT® removed before 5 years were also asked about who had made the
decision for removal and where did they go to get NORPLANT® removed. Data in Table 11 show
that about two-thirds (62%) of those women reported that the decision was made by themselves,
while an additional 29% of women stated that the physician recommended removal. Only a few
women (6%) said that their husbands asked them to have NORPLANT® removed.
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The majority (58%) of the removal cases
occurred in the same health facilities where
NORPLANT® NORPLANT® had been
inserted. It is interesting to note that about onefifth (21%) of the women went to a private
doctor to have NORPLANT® removed. Another
17% reported that they went to a different
university hospital for NORPLANT® removal
(Table 11). Women who did not have
NORPLANT® removed at the same health
facility were asked about the reason (not shown
in Table 11). About one-third of women in this
group (n=45) indicated that the physician who
made the insertion couldn’t remove the
capsules. An additional one-half of the women

Table 11: Decision Makers and Place of Removal as
Reported by Discontinued Users (n=103)
Percent
Who made the decision to remove
NORPLANT®?
Client
62.1
Doctor
29.1
Husband
5.8
Relatives
1.0
Friends
1.9
Place of removal
Same place of insertion
Private doctor
Another university hospital
Another teaching hospital
MOHP hospital
Other

58.3
21.4
16.5
1.0
1.9
1.0

Number of removal sessions
1
2
3+

90.3
6.8
2.9

Source: home interviews

said that they were referred to another health facility for removal and about 12% said that the
private physician is better (not shown in a table or graph).
The majority of women were able to get NORPLANT® removed through making one visit to the
health facility (90%), (Table 11). Other women (about one-tenth), however, had to make at least
two visits to the health facility
to get NORPLANT® removed.
These findings indicate that

Figure 21: Duration of NORPLANT® Use (years)
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additional one-third reported
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use for 1-2 years (see Figure 21). Close to one-third of women reported a duration of 2-4 years of
use. Only 3 percent of women reported a period of 4-less than 5 years. This group is approaching
the end of effective use
duration and will be due

Figure 22: Duration of NORPLANT® Use (years)
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implants removed fairly
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Mean duration of use= 1.4 years

soon after insertion (less than one year use). Between 10-13% used NORPLANT® for 1-2, 2-3 or 34 years before removal. Women who had NORPLANT® removed in about due time (in fact beyond
5 years) represented only one percent of this group. Overall, the average duration of NORPLANT®
use among continuers and discontinuers was 1.8 and 1.4 years, respectively. The short average
duration of NORPLANT®
use among discontinuers

Figure 23 : Side Effects Experienced during
NORPLANT® Use
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NORPLANT® discontinuers reported experiencing NORPLANT® side-effects compared to the
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continuers group (see Figure 23). Among the discontinuers group the most frequently reported sideeffects experienced were severe bleeding (47%), weight changes (39%), menstrual cycle
disturbances (35%) and suffering continuous headache (28%). For the continuers group, the most
frequently reported side-effects for NORPLANT® were menstrual cycle disturbance (30%),
amenorrhoea (18%), weight changes (17%) and pain at site of insertion (13%) (Figure 23).
These types of reported side-effects conform with findings indicated by other studies (Institute of
Medicine, 1998, EFCS, 1995,
National Family Planning
Coordinating Board, Indonesia 1993,
Hassan et al, 1992). Table 12
provides additional data on the
experience with NORPLANT®
removal. Discontinued users were
asked if the rods were removed
easily. About one-half of them

Table 12: Experience with NORPLANT® Removal as Reported by
Discontinued Users
Percent
Was the rods’ removal easy? (n=103)
Yes
48
No
52
Why was it difficult? (n=54)
Pain at capsule site
43
Excessive bleeding in arm
15
Only local anesthesia given
17
Too long time for removal
37
Fibrosis around implanted capsules
20
Other
10
Source: home interviews

reported that rods were not easily
removed. Among this group, major
reasons reported for difficulty in
removing the rods were having pain
at capsule site (43 percent) and too
long a time for removal (37 percent).
Another perspective of how
NORPLANT® users experience
side-effects is given in Table 13.
About 58% of the women who had
NORPLANT® inserted 1-4 years
ago (n=624) reported health
problems that they thought were
related to NORPLANT® use. The
most frequently mentioned problems
were menstrual cycle disturbance

Table 13: Tolerance of Side-effects and Medical Assistance
Received
Percent
Have you experienced any body changes / health problems
that you think it happened due to NORPLANT® use?
(n=624)
Yes
No
What were these problems? (n=363)
Menstrual cycle disturbances
Weight change
Abdominal pain
Continuous headache
Other pain
General debility
Other
Have you consulted a physician about these problems?
(n=363)
Yes
No
What was the physician’s advice? (n=196)
Reassured me
Recommended NORPLANT® removal
Gave me treatment
Advised that changes are not due to NORPLANT®
Other
Source: home interviews

58
42
58
33
12
26
28
19
31
54
46
28
14
50
7
2

(58%), suffering from continuous
headache (26%) and having some body pain (28%). Only about one-half of women who faced
medical problems went to physicians seeking medical advice. Among those women who sought
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care from a physician, 28% reported that the doctor reassured them that these problems were simple
and normal with NORPLANT® use.
However one-half of the

Figure 24: Switching to another Method among
NORPLANT® Discontinuers

women who sought care
received treatment, while

If so, what methods
you

Have you used any FP
after NORPLANT®

about 14% of the women
were advised by the
physicians to have

IUD 38%

Yes
71%

NORPLANT® removed.

No
29%

Women who had

Pill 33%

NORPLANT® removed

Injectables 26%

were asked if they had

Other 14%

switched to another family

(n=73)

Discontinuers: ( n=103)

planning method after
removal. Seventy-one

Source: home interviews

percent answered affirmatively (see Figure 24). Among this group, about 38% switched to the IUD,
about 33% switched to the pill, and about 26% began using injectables.
Among all of the sample
women who began using
NORPLANT® between 1-

Figure 25 : Selected Indicators on Client
Satisfaction with NORPLANT® Method/Service

4 years ago, the vast
majority reported general
satisfaction with the

Comfortable /happy with NORPLANT use

majority (97%) reported
that the insertion

having no felt pain or fear

97

Haven't felt pain/fear during insertion

80

Will recommend NORPLANT to others

61

Got NORPLANT free but would pay if required
(n=378)*

90

Not annoyed by capsules being recognized (n=139)

procedure went well with
about 80% reporting

90

No problems faced during insertion

method, and the services
(Figure 25). The large

83

Intend to use NORPLANT to end of period
(n=521)

97
0

20

60
80
40
Percent answering yes

100

*Other women (n=236) paid for the capsules, mean payment= LE 19. 2

Source: home interview , (n=624)

during the insertion procedure. Almost all women who reported that the capsules were recognized
by others in their arms (n=139) indicated that they were not annoyed because of that. About 90
percent of women who were still using NORPLANT® intend to continue NORPLANT® use to the
end of the five-year duration (figure 25). Almost two-thirds (61%) of all women stated that they
would recommend NORPLANT® to others.
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OVERVIEW OF FINDINGS AND PROGRAM IMPLICATIONS
These study’s findings provide comprehensive information on how NORPLANT® services have
been administered and used through the on-going Introduction Program that is now approaching
five years of operation.
Major study findings with program implications are highlighted below:
1. The record system audit indicated that about one-third of clients available in clinic registers
were not entered in the central MOHP MIS. The following are possible reasons:
•

Clinics ran out of supplies of client information sheets that are completed at the clinic level
for women who had NORPLANT® inserted and sent to the central MIS (monitoring visits
during field data collection showed that this could be the case for some clinics).

•

Client information sheets may have been completed at clinics and sent to central MIS, but
some client information items were missing and the sheets were returned to the clinics for
adding the missing information items. Some of these sheets may not have been sent back
again to central MIS.

2. Even in situations where client records existed in both the MIS and clinic registers, cases with
completely matched client information data (perfect fit) were very few. While data on the date
of insertion were highly accurate (mean concordance in this information item at MIS and clinic
registers was 0.95), data on the
due date for removal and
information on women’s
addresses were defective and
incomplete (mean concordance
was 0.40 and 0.24, respectively).
3. Based on the above findings,
and keeping in mind the fact that
only 56% of women’s addresses
were complete enough for the field worker to locate, it appears that special mechanisms need to
be developed in order to strengthen the capability of NORPLANT® MIS to identify and locate
women eligible for removal.
4. The study also indicated that, although a client follow-up system is in place to inform women
who had NORPLANT® inserted about the schedule of follow-up visits (through giving the
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woman a card), this system is not completely functional. About 15 percent of the women
reported that service providers did not give them a card. Moreover, about two-fifths of the
women indicated that they received a card but that it was later lost. Furthermore, if women did
not return to clinic for follow-up visits there was no system in place at the clinic to follow up
women who failed to make the visits to clinics. The implication of the above findings is that
some women eligible for removal might not be reached unless women themselves can
remember the due date for removal and seek removal service.
5. The study findings indicated that physicians reported that they need more training on
NORPLANT® insertion and removal (reported by 23 and 53 percent, respectively). Also,
physicians reported facing some difficulties during removal, including breaking of rods,
incorrect insertion, and difficulties in identifying the exact site of the implanted capsules. These
findings call for the need for structured assessment of both the quality of training received as
well as physicians’ training needs.
6. Women who had NORPLANT® removed (n= 103) did report difficulties with the removal
experience. About two-fifths of those women went to a health facility for removal other than the
facility where the NORPLANT® was inserted. About one-tenth of the women complained that
they had to make at least two visits to the clinic to get NORPLANT® removed. Additionally,
one-half of women said that the removal procedure was difficult. Among this latter group, 43%
said that they felt pain at the site of capsules and 47% reported too long a removal time.
7. The majority of women who had NORPLANT® inserted 1-4 years ago (n=624) were
comfortable with NORPLANT® (83%). About 61% of them reported that they will recommend
NORPLANT® to others. The majority of them wanted to terminate childbearing (91%).
According to them, they liked NORPLANT® because it could be used for five years, its use is
associated with fewer side-effects, they do not need to remember to do anything to avoid
pregnancy, and it is an effective method. Also, many women (two-fifths) did not perceive any
disadvantages for NORPLANT®. Furthermore, the majority of women who received the method
free (about 90%) said that they would pay for the method if requested. However, among this
group, the majority of women who discontinued NORPLANT® use (n=103) were less satisfied
with the method. Only 42 percent of this group reported that they were comfortable with
NORPLANT® use and 28 percent said that they will recommend NORPLANT® to others.
8. Despite overall satisfaction with the NORPLANT® method, many women reported being
worried about side-effects. Experiencing severe bleeding, weight changes, menstrual cycle
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disturbances, headache and pain at insertion site were the most frequently reported-side effects.
In general, about one-half of women who had NORPLANT® inserted 1-4 years ago reported
facing health problems that they thought were related to NORPLANT® use. Only about one-half
sought medical advice. In one-half of these cases (n=196), the physician gave women
medication. It is not known to what extent medication given in such situations has been
discussed and/or recommended during training/preparing NORPLANT® service provision
protocols.
9. Irregular supplies of NORPLANT® capsules seem to occur with implications for free and
informed method choice as well as for exposure to unplanned pregnancies. About one-half of
physicians said that they face occasional shortages of NORPLANT® supplies. In this situation,
physicians reported that they ask the woman who requested NORPLANT® insertion to come
later when supplies are made available, or they ask her to use another method. Many physicians
(42%) said that they give women a temporary method until NORPLANT® supplies become
available.
10. The study findings did not suggest the presence of negative attitudes by service providers
toward NORPLANT® as a family planning method. Physicians insert NORPLANT® upon
request by women when they think that there is no contraindication for NORPLANT®. It is
noted that the study was only conducted in some NORPLANT® service delivery sites, and the
sample of providers is not necessarily representative of all Egyptian physicians and nurses.
11. The study findings indicated that women received partial counseling and information on
NORPLANT®. Only two-fifths of the new users reported being told about side-effects and
about one-half said that they were told about insertion procedures. Also, follow-up information
given to women after NORPLANT® insertion was not complete. Only one-fourth of the new
users were told about the due date for removal (though almost of them were told that
NORPLANT® use duration is five years), and two-fifths were told about where to go for
removal.
12. The findings reflected a lack of consensus among physicians regarding NORPLANT®
contraindication. There also seems to be a need to train providers about the most appropriate
candidates for NORPLANT® use.
13. The study findings indicated that about one-half of women who discontinued NORPLANT® use
had the rods removed before the second year of use. This raises the question of whether those
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women were properly counseled about potential NORPLANT® side-effects at the time of the
insertion. Also, do health providers adequately inform women about advantages and
disadvantages of NORPLANT® and determine candidates for NORPLANT® use?
14. The role of media was called upon in promoting NORPLANT® use. Lack of media advertising
about NORPLANT® was reported by both physicians and nurses as the number one problem
facing the NORPLANT® Introduction Program.

RECOMMENDATIONS
Quality of Care
•

Provide additional training to service providers involved in NORPLANT® service provision
at both teaching hospitals and MOHP health facilities. The training should target promoting
both provider technical knowledge and clinical skills regarding counseling and information
given to clients, identifying appropriate candidates for NORPLANT® use, NORPLANT®
contraindication, as well as NORPLANT® insertion and removal. Also, provider training
programs should include medications prescribed by physicians for side-effects. An
assessment of the specific training needs for quality NORPLANT® service provision is
needed.

•

Promote accessibility to removal services and the quality of these services. As women depend
on service providers to both insert and remove the rods, it should be equally easy for women
to get NORPLANT® removed and inserted.

•

Develop adequate client follow-up systems. At a minimum, due dates for removal should be
carefully observed by clinic staff and clients should be contacted and advised for removal.

•

Review the need to ensure regular supplies of NORPLANT® and the complex nature of the
NORPLANT® service provision system compared with other family planning methods before
decisions are made to extend NORPLANT® services to additional health facilities. Keeping
these important issues in mind, appropriate decisions might be taken on whether to expand
NORPLANT® services horizontally through increased number of service delivery units or
vertically through continuous quality improvement and increased demand and client
satisfaction.
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•

Develop an integrated quality oriented monitoring and evaluation system for NORPLANT®
service delivery sites.

Tracking and locating NORPLANT® users
•

Develop appropriate mechanisms to promote central MIS capacity to identify and locate
women eligible for NORPLANT® removal. Information items included in clients’ records
may be minimized to include only basic information needed to track women efficiently to
ensure that the rods are removed or replaced when they become no longer effective. The
central MIS should be periodically tested for accuracy and completeness of its information. In
addition, a decentralized MIS (at the district or clinic level) could be established if the MOHP
plans to generate more detailed information regarding the pool of women who seek
NORPLANT® insertion.

•

Establish clear guidelines requesting clinic staff to give due attention to recording complete
information on women’s addresses as well as the address of one of their relatives or
neighbors according to instructions currently in place. This would greatly promote efforts to
locate women eligible for removal.

Program Sustainability
•

Reconsider the decision to provide NORPLANT® free of charge, in view of the findings on
women’s readiness to pay for NORPLANT® among the majority of women who received a
free method. A modest user’s fee may be introduced as a first step towards making the
NORPLANT® program sustainable.

IEC
•

Develop further IEC components that promote women’s knowledge about NORPLANT® as a
family planning method. This would help expand contraceptive choice, stress the need to
return to clinics to receive follow-up services, and alert women about the need for removal
after five years.
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